sur Adolore Biotherapeutics, Inc.
Adolore BioTherapeutics Publishes Promising Preclinical Data on Non-Opioid Analgesic Gene Therapy
Adolore BioTherapeutics has announced strong preclinical results for its non-opioid analgesic gene therapy, ADLR-1001, designed to treat chronic knee pain caused by osteoarthritis (OA). These findings validate the company's method of delivering a non-opioid analgesic minigene to targeted sensory neurons through local administration.
The data provide robust proof-of-concept for ADLR-1001, showing prolonged therapeutic effects and indicating a significant reduction in chronic knee pain due to OA. These effects were achieved via the activation of Kv7 voltage-gated potassium channels in small sensory neurons.
Importantly, the study observed no adverse events, and animals treated with ADLR-1001 exhibited normalized weight-bearing and activity levels. The company is set to continue development with support from an NIH/NINDS UH3 HEAL Grant, aiming for clinical studies by 2026.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Adolore Biotherapeutics, Inc.